Our Team
Chemists Building for Discovery
Synthetic and medicinal chemists with experience spanning new methods development, hit-to-lead, and IND-stage programs.
Leadership
The people running the platform
Hover over a photo to read more.
James Brewster, Ph.D.
Chief Executive Officer
James is an experienced chemist with knowledge across the drug discovery process. He led project and chemistry efforts at Harvard University, Pfizer, and Think, spanning antibody drug-conjugate development and small molecule inhibitors. At Pfizer Boulder he led new methods development, pioneering new photo-catalyzed chemistry and has experience across the chemical and medical sciences.
Patrick Barbour, Ph.D.
Associate Director
Patrick brings more than 15 years of oncology medicinal chemistry from Array Biopharma and Pfizer, where he led programs from hit-finding through candidate nomination, five of which advanced to IND. His expertise spans organometallic chemistry and the synthesis of complex small molecules.
Gregory Thiabaud, Ph.D.
Associate Director
Gregory brings more than 15 years across chemistry and materials science, with over 15 publications spanning the chemical and biological sciences. He is a leading expert in inorganic chemistry, materials science, and solid-phase synthesis.
Scientific Advisory Board
Advisors who have done it before
Hover over a photo to read more.
Jonathan L. Sessler, Ph.D.
UT Austin · NAS Member
Jonathan holds the R.P. Doherty, Jr. — Welch Regent Chair in Chemistry at The University of Texas at Austin, and is notable for his pioneering work in organic and inorganic synthesis and bioinorganic medicinal chemistry. He was elected a member of the U.S. National Academy of Sciences, and co-founded Pharmacyclics, Inc., sold to AbbVie for $21 billion in 2015.
Ronald J. Hinklin, Ph.D.
Pfizer · Array Biopharma
Ron is an accomplished leader and scientist with over 22 years of experience in medicinal chemistry. He was a Senior Director at Pfizer and, during his time there and at Array Biopharma, has led or contributed to 8 programs that advanced to IND. Ron is co-inventor on 27 patents and author on 25 papers.
Pat Confalone, Ph.D.
Roche · DuPont · Bristol-Myers Squibb
Pat has over fifty years in drug discovery, leading Medicinal Chemistry and Chemical Process R&D groups at Roche, DuPont, DuPont Merck, and Bristol-Myers Squibb. He helped discover or develop Cozaar™, Rynaxypyr™, Sustiva™, Cyazypyr™, Zorvec™, and NexGard™, has published over 140 papers and holds more than 50 U.S. patents. He is a Fellow of the AAAS and an ACS Fellow.
Work with us
We are always interested in talking with chemists, partners, and collaborators.
Cime Therapeutics 